Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

CRNX 11.15.2024

Full Press ReleaseSEC FilingsOur CRNX Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Crinetics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - Crinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.10.2025 - Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities

SAN DIEGO,Nov. 15, 2024(GLOBE NEWSWIRE) --Crinetics Pharmaceuticals, Inc.(Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held inNew York, NY, and both theCiti Global Healthcare Conferenceand the Evercore 7th AnnualHealthCONx Conferenceare taking place inMiami, FL.

Evercore 7th AnnualHealthCONx ConferenceFireside chatonTuesday, December 3, 2024at7:30 a.m. Eastern TimeWebcast linkHERE

Citi Global Healthcare ConferenceFireside chatonWednesday, December 4, 2024at9:30 a.m. Eastern TimeWebcast linkHERE

Piper Sandler 36th Annual Healthcare ConferenceFireside chatonThursday, December 5, 2024at1:00 p.m. Eastern TimeWebcast linkHERE

The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website atwww.crinetics.com/events.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUTCRINETICS PHARMACEUTICALSCrinetics Pharmaceuticalsis a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com(858) 345-6340

Media:Natalie BadilloHead of Corporate Communicationsnbadillo@crinetics.com(858) 345-6075

Primary Logo

Source: Crinetics Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com